CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...

Monoclonal antibodies are a key tool doctors use to treat severe COVID-19, and are particularly important for severely immunocompromised patients or people who cannot get vaccinated.